Torii K, Iida K, Miyazaki Y, Saga S, Kondoh Y, Taniguchi H, Taki F, Takagi K, Matsuyama M, Suzuki R
Department of Internal Medicine II, Faculty of Medicine, University of Nagoya, Japan.
Am J Respir Crit Care Med. 1997 Jan;155(1):43-6. doi: 10.1164/ajrccm.155.1.9001287.
This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult respiratory distress syndrome (ARDS). We determined the concentrations of these enzymes in the bronchoalveolar lavage fluid (BALF) from patients with ARDS using newly developed sensitive one-step sandwich enzyme immunoassay methods. BALF obtained from the 17 patients and eight healthy volunteer control subjects were also used for the analysis of the number of the cellular component. Concentrations of the 7S portion of type IV collagen and laminin in the BALF were measured as markers of basement membrane disruption. In the BALF from the ARDS patients, the concentrations of MMP-2 (66.7 +/- 57.0 ng/ml versus < 7.0 ng/ml for controls, p < 0.01) and MMP-9 (118.0 +/- 309.3 ng/ml versus 9.0 +/- 9.5 ng/ml for controls, p < 0.05), and the specific inhibitor of MMP-9 (TIMP-1) (161.0 +/- 145.0 ng/ml versus < 50 ng/ml for controls, p < 0.01) were significantly higher compared with those for healthy control subjects. In the ARDS patients, the concentrations of MMP-2 correlated both with those of 7S collagen and laminin; MMP-9 with the concentration of 7S collagen and the number of neutrophils. These findings suggest that the increased concentration of collagenolytic MMPs in lung plays a role in the pathogenesis of ARDS.
本研究旨在调查IV型胶原溶解基质金属蛋白酶(MMPs;72 kDa IV型胶原酶 [MMP-2]、92 kDa IV型胶原酶 [MMP-9])及其各自的特异性组织抑制剂(TIMP-2和TIMP-1)在成人呼吸窘迫综合征(ARDS)发病过程中可能的参与情况。我们使用新开发的灵敏一步夹心酶免疫测定法,测定了ARDS患者支气管肺泡灌洗液(BALF)中这些酶的浓度。从17例患者和8名健康志愿者对照受试者获取的BALF,也用于分析细胞成分数量。测定BALF中IV型胶原7S部分和层粘连蛋白的浓度,作为基底膜破坏的标志物。在ARDS患者的BALF中,MMP-2的浓度(66.7±57.0 ng/ml,对照组<7.0 ng/ml,p<0.01)和MMP-9的浓度(118.0±309.3 ng/ml,对照组9.0±9.5 ng/ml,p<0.05)以及MMP-9的特异性抑制剂(TIMP-1)(161.0±145.0 ng/ml,对照组<50 ng/ml,p<0.01)与健康对照受试者相比显著更高。在ARDS患者中,MMP-2的浓度与7S胶原和层粘连蛋白的浓度均相关;MMP-9与7S胶原的浓度和中性粒细胞数量相关。这些发现表明,肺中胶原溶解MMPs浓度的增加在ARDS的发病机制中起作用。